← Back to Clinical Trials
Recruiting NCT07047573

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Trial Parameters

Condition Lung Cancer (Diagnosis)
Sponsor Zhao Jun
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-06-01
Completion 2026-06
Interventions
PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer

Brief Summary

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Eligibility Criteria

Inclusion Criteria: * Patient underwent a ct examination * Patient was confirmed to have pulmonary nodules * Patient has been determined to undergo surgical treatment * There are clear pathological results * The clinicopathological data are complete Exclusion Criteria: * Patient has no ct examination results * Refuse surgical treatment * Patient has no clear pathological diagnosis * Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C. * Patients with tumor emergencies that require immediate treatment. * Poor vascular conditions. * Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy. * Patients with hematogenic infectious diseases, such as HBV. * Patients with psychiatric disorders or severe mental illnesses. * Patients who have difficulty communicating or are unable to be followed up for a long time

Related Trials